Sacituzumab govitecan-hziy (Trodelvy), a trophoblast cell-surface antigen 2 (Trop-2)-targeted antibody-SN-38 conjugate, has been approved for relapsed or refractory TNBC (9–12) and other cancers (13–16) following standard therapies. This evidence concerns the gene TACSTD2 and cancer.